C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) G01N 33/53 (2006.01) C12P 19/34 (2006.01) G06F 19/00 (2006.01)
Patent
CA 2547901
A method for determining the prognosis of a patient presenting with chronic lymphocytic leukaemia comprising: a)isolating a population of lymphocytes from a blood sample taken from said patient; b) examining the DNA of said lymphocytes in order to determine the mutation status of V H gene; c) determining the expression of CD38; d)determining the expression of ZAP-70; and e) feeding the information from steps b), c) and d) into the following equation in order to determine the protein tyrosine phosphorylation of said lymphocytes: (see above formula) where: PY Post IgM = CLL cell protein tyrosine phosphorylation (following IgM stimulation); CD38 = CLL cell surface presence of CD38, expressed as a %; Percentage in this context means the percentage of CLL cells with greater fluorescence than the isotype-matched control. V H status = V H gene mutation status, expressed as a % homology to wild type; and ZAP-70 = CLL cell ZAP-70 expression, expressed as a %. Percentage in this context means the percentage of CLL cells with equal or greater fluorescence than the T-cell population in the same sample.
Brennan Paul
Fegan Chris
Griffiths Jeff D.
Pepper Chris
Price Lloyd Naomi
Mcfadden Fincham
University College Cardiff Consultants Limited
LandOfFree
Chronic lymphocytic leukaemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chronic lymphocytic leukaemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chronic lymphocytic leukaemia will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1378363